<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Vaccines (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Vaccines (Basel)</journal-id><journal-id journal-id-type="publisher-id">vaccines</journal-id><journal-title-group><journal-title>Vaccines</journal-title></journal-title-group><issn pub-type="epub">2076-393X</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40006697</article-id><article-id pub-id-type="pmc">PMC11860608</article-id><article-id pub-id-type="doi">10.3390/vaccines13020150</article-id><article-id pub-id-type="publisher-id">vaccines-13-00150</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Characterization and Protective Efficacy of a <italic toggle="yes">Salmonella&#x000a0;Typhimurium</italic> ATCC 14028 <italic toggle="yes">sptP</italic> Mutant as a Live Attenuated Vaccine Candidate</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zhou</surname><given-names>Nanlong</given-names></name><xref rid="af1-vaccines-13-00150" ref-type="aff">1</xref><xref rid="fn1-vaccines-13-00150" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Ding</surname><given-names>Yonghui</given-names></name><xref rid="af1-vaccines-13-00150" ref-type="aff">1</xref><xref rid="fn1-vaccines-13-00150" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>He</surname><given-names>Ting</given-names></name><xref rid="af1-vaccines-13-00150" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Sun</surname><given-names>Yuling</given-names></name><xref rid="af1-vaccines-13-00150" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Hongfang</given-names></name><xref rid="af1-vaccines-13-00150" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Huang</surname><given-names>Meiling</given-names></name><xref rid="af2-vaccines-13-00150" ref-type="aff">2</xref><xref rid="c1-vaccines-13-00150" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Tiansen</given-names></name><xref rid="af1-vaccines-13-00150" ref-type="aff">1</xref><xref rid="c1-vaccines-13-00150" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Paganelli</surname><given-names>Roberto</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>D&#x02019;Amelio</surname><given-names>Raffaele</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-vaccines-13-00150"><label>1</label>School of Tropical Agriculture and Forestry, Hainan University, Haikou 570100, China; <email>nanlongzhou@163.com</email> (N.Z.); </aff><aff id="af2-vaccines-13-00150"><label>2</label>Key Laboratory of Tropical Translational Medicine of Ministry of Education, Hainan Key Laboratory for Research and Development of Tropical Herbs, School of Pharmacy, Hainan Medical University, Haikou 571199, China</aff><author-notes><corresp id="c1-vaccines-13-00150"><label>*</label>Correspondence: <email>mgling213@163.com</email> (M.H.); <email>tsli_918@163.com</email> (T.L.)</corresp><fn id="fn1-vaccines-13-00150"><label>&#x02020;</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="epub"><day>31</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>13</volume><issue>2</issue><elocation-id>150</elocation-id><history><date date-type="received"><day>07</day><month>12</month><year>2024</year></date><date date-type="rev-recd"><day>23</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>27</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Background: <italic toggle="yes">Salmonella&#x000a0;Typhimurium</italic> poses a substantial health risk to both humans and animals. This study evaluated the potential of using the <italic toggle="yes">Salmonella&#x000a0;Typhimurium</italic> &#x00394;<italic toggle="yes">sptP</italic> mutant as a live-attenuated vaccine candidate by constructing it through homologous recombination and assessing its key biological properties, including growth characteristics, immunogenicity, and protective efficacy. Methods: We generated the &#x00394;<italic toggle="yes">sptP</italic> mutant through targeted gene deletion, ensuring the preservation of the bacterial strain&#x02019;s growth and stability. In vitro and in vivo assays were performed to compare the invasive capabilities between the mutant and the wild-type strains. Specifically, we examined the invasion into RAW264.7 murine macrophages and mice. Furthermore, the virulence of the mutant was evaluated by determining the median lethal dose (LD<sub>50</sub>). To evaluate immunogenicity and protection, mice were immunized with 2 &#x000d7; 10<sup>4</sup> CFUs of the &#x00394;<italic toggle="yes">sptP</italic> mutant, followed by a booster immunization, and then challenged with a virulent strain. Results: The &#x00394;<italic toggle="yes">sptP</italic> mutant exhibited no significant changes in growth characteristics or genetic stability compared to the wild-type strain. However, it demonstrated a significantly diminished capacity for invasion in both murine macrophages and mice. The LD<sub>50</sub> for the mutant was 39.92-fold higher than that of the wild-type, indicating a marked reduction in virulence. Mice immunized with the &#x00394;<italic toggle="yes">sptP</italic> mutant and administered a booster immunization exhibited 87.5% protection against challenge with a virulent strain, as compared to the PBS control group. Moreover, the mutant induced IgG antibody levels comparable to those induced by the wild-type strain. Conclusions: The &#x00394;<italic toggle="yes">sptP</italic> mutant of <italic toggle="yes">Salmonella&#x000a0;Typhimurium</italic> exhibits markedly reduced virulence while retaining robust immunogenicity and protective efficacy. These findings suggest that the &#x00394;<italic toggle="yes">sptP</italic> mutant is a promising candidate for a live-attenuated vaccine, potentially providing an effective strategy to prevent <italic toggle="yes">Salmonella&#x000a0;Typhimurium</italic> infections.</p></abstract><kwd-group><kwd><italic toggle="yes">Salmonella&#x000a0;Typhimurium</italic></kwd><kwd><italic toggle="yes">sptP</italic></kwd><kwd>live attenuated vaccine</kwd><kwd>mutant</kwd><kwd>immunogenicity</kwd></kwd-group><funding-group><award-group><funding-source>Hainan Provincial Natural Science Foundation of China</funding-source><award-id>823RC468</award-id></award-group><award-group><funding-source>Hainan university scientific research start-up fund</funding-source><award-id>KYQD(ZR)1936</award-id></award-group><award-group><funding-source>earmarked fund for the Agriculture Research System in Hainan Province</funding-source><award-id>HNARS2022-2-G05</award-id></award-group><funding-statement>This study was supported by the Hainan Provincial Natural Science Foundation of China (Grant No. 823RC468), Hainan university scientific research start-up fund [Grant No. KYQD(ZR)1936], and the earmarked fund for the Agriculture Research System in Hainan Province (Grant No. HNARS2022-2-G05).</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-vaccines-13-00150"><title>1. Introduction</title><p><italic toggle="yes">Salmonella Typhimurium</italic>, a Gram-negative bacterium, is widely distributed across various environments, including livestock and wild-animal populations [<xref rid="B1-vaccines-13-00150" ref-type="bibr">1</xref>]. This bacterium exhibits conditional pathogenicity and poses a substantial health risk to humans and domestic animals by being transmitted through contaminated food and water sources [<xref rid="B2-vaccines-13-00150" ref-type="bibr">2</xref>]. Infection with <italic toggle="yes">Salmonella Typhimurium</italic> can cause a range of intestinal diseases in both animals and humans [<xref rid="B3-vaccines-13-00150" ref-type="bibr">3</xref>], causing systemic symptoms such as gastroenteritis and septicemia, as well as tissue and organ damage [<xref rid="B4-vaccines-13-00150" ref-type="bibr">4</xref>]. Such infections not only increase livestock mortality but also reduce productivity and growth rates, resulting in significant economic losses for the agricultural sector [<xref rid="B5-vaccines-13-00150" ref-type="bibr">5</xref>].</p><p><italic toggle="yes">Salmonella Typhimurium</italic> primarily spreads through the fecal&#x02013;oral route, invades the host [<xref rid="B6-vaccines-13-00150" ref-type="bibr">6</xref>], and subsequently colonizes the host&#x02019;s macrophages [<xref rid="B5-vaccines-13-00150" ref-type="bibr">5</xref>]. By utilizing a distinct array of unique virulence factors and typhoid toxins, the infection symptoms in the host progressively develop, and virulence proteins interact with the host cells to facilitate bacterial survival and proliferation within them [<xref rid="B7-vaccines-13-00150" ref-type="bibr">7</xref>,<xref rid="B8-vaccines-13-00150" ref-type="bibr">8</xref>,<xref rid="B9-vaccines-13-00150" ref-type="bibr">9</xref>]. The region of the <italic toggle="yes">Salmonella</italic> genome encoding virulence-related genes, known as the Salmonella Pathogenicity Island (SPI) [<xref rid="B10-vaccines-13-00150" ref-type="bibr">10</xref>], which plays a crucial role in <italic toggle="yes">Salmonella</italic>&#x02019;s invasion and disease processes. Notably, SPI-1 and SPI-2 are closely linked to its pathogenic potential [<xref rid="B11-vaccines-13-00150" ref-type="bibr">11</xref>,<xref rid="B12-vaccines-13-00150" ref-type="bibr">12</xref>].</p><p>Currently, antibiotics remain a highly effective means for controlling <italic toggle="yes">Salmonella Typhimurium</italic> infections. However, their prolonged use has raised growing concerns regarding antibiotic residues and the development of bacterial resistance [<xref rid="B13-vaccines-13-00150" ref-type="bibr">13</xref>,<xref rid="B14-vaccines-13-00150" ref-type="bibr">14</xref>,<xref rid="B15-vaccines-13-00150" ref-type="bibr">15</xref>]. As a result, vaccination has emerged as an effective preventive strategy against <italic toggle="yes">Salmonella Typhimurium</italic> infection [<xref rid="B16-vaccines-13-00150" ref-type="bibr">16</xref>]. With the expanding body of research into <italic toggle="yes">Salmonella Typhimurium</italic>&#x02019;s pathogenic mechanisms, the engineering of attenuated strains by deleting virulence genes is becoming increasingly prevalent in the development of such vaccines [<xref rid="B17-vaccines-13-00150" ref-type="bibr">17</xref>,<xref rid="B18-vaccines-13-00150" ref-type="bibr">18</xref>,<xref rid="B19-vaccines-13-00150" ref-type="bibr">19</xref>,<xref rid="B20-vaccines-13-00150" ref-type="bibr">20</xref>]. The SptP protein, a critical virulence factor of <italic toggle="yes">Salmonella Typhimurium</italic> [<xref rid="B21-vaccines-13-00150" ref-type="bibr">21</xref>,<xref rid="B22-vaccines-13-00150" ref-type="bibr">22</xref>], triggers the reorganization of the host cell actin cytoskeleton upon bacterial entry, thereby facilitating invasion [<xref rid="B23-vaccines-13-00150" ref-type="bibr">23</xref>,<xref rid="B24-vaccines-13-00150" ref-type="bibr">24</xref>]. SptP exerts a crucial regulatory role in the intracellular survival of <italic toggle="yes">Salmonella Typhimurium</italic>.</p><p>Consequently, we constructed a <italic toggle="yes">sptP</italic> gene mutant of <italic toggle="yes">Salmonella Typhimurium</italic> using the homologous recombination technique. Subsequently, we characterized the mutant strain&#x02019;s biological properties, such as growth dynamics, immunogenic potential, and invasive capacity, and preliminarily assessed its protective efficacy to ascertain whether the <italic toggle="yes">sptP</italic> gene deletion impacts the bacterium&#x02019;s virulence. It is essential to research and develop live attenuated vaccines to prevent and control <italic toggle="yes">Salmonella Typhimurium</italic> infection.</p></sec><sec id="sec2-vaccines-13-00150"><title>2. Materials and Methods</title><sec id="sec2dot1-vaccines-13-00150"><title>2.1. Bacterial Strains, Plasmids, and Primers</title><p>The wild-type strain of <italic toggle="yes">Salmonella Typhimurium</italic> ATCC14028 used in this study was maintained in our laboratory. The <italic toggle="yes">sptP</italic> gene mutant (ATCC14028&#x00394;<italic toggle="yes">sptP</italic>) was constructed via homologous recombination using plasmids pACYC184 and pKD46, together with the primers <italic toggle="yes">sptP</italic>-cat-F and <italic toggle="yes">sptP</italic>-cat-R. Strains were cultured in Luria&#x02013;Bertani (LB) broth containing 1% (wt/vol) tryptone, 0.5% (wt/vol) yeast extract, and 0.5% (wt/vol) NaCl, or on LB agar plates with an additional 1.5% (wt/vol) agar, depending on the experimental needs. When required, ampicillin (Amp, 50 &#x000b5;g/mL) or chloramphenicol (Cm, 25 &#x000b5;g/mL) was supplemented into the medium. The sequences of the primers used in this study are provided in <xref rid="vaccines-13-00150-t001" ref-type="table">Table 1</xref>.</p></sec><sec id="sec2dot2-vaccines-13-00150"><title>2.2. Construction of the sptP Mutant</title><p>The <italic toggle="yes">sptP</italic> gene mutant (ATCC14028&#x00394;<italic toggle="yes">sptP</italic>) was constructed using the suicide vector pKD46 through homologous recombination. Briefly, the chloramphenicol resistance cassette was PCR-amplified from pACYC184 using the primers <italic toggle="yes">sptP</italic>-cat-F and <italic toggle="yes">sptP</italic>-cat-R, which incorporated 50 bp homology arms at both the 5&#x02032; and 3&#x02032; ends of the <italic toggle="yes">sptP</italic> locus. The purified PCR product was then introduced into competent <italic toggle="yes">Salmonella Typhimurium</italic> cells containing pKD46 by electroporation. Single-crossover mutants were selected on chloramphenicol-containing LB agar plates and verified by PCR using the primers <italic toggle="yes">sptP</italic>-out-F and <italic toggle="yes">sptP</italic>-out-R. Sequencing further confirmed the successful disruption of the <italic toggle="yes">sptP</italic> gene.</p></sec><sec id="sec2dot3-vaccines-13-00150"><title>2.3. Identification of the Biological Characteristics of ATCC14028&#x00394;sptP In Vitro</title><p>To evaluate the growth characteristics of the ATCC14028&#x00394;<italic toggle="yes">sptP</italic> mutant, we performed colony morphology analysis and biochemical identification on MacConkey agar plates. The findings were then compared with those of the wild-type ATCC14028 strain. Following this, the growth kinetics and genetic stability of both strains were examined. Both the wild-type ATCC14028 and ATCC14028&#x00394;<italic toggle="yes">sptP</italic> strains were cultured under conditions of 180 rpm agitation at 37 &#x000b0;C, with optical density (OD<sub>600</sub>) measurements recorded every 2 h over a 36 h period. Under these conditions, the ATCC14028&#x00394;<italic toggle="yes">sptP</italic> strain was passaged for up to 30 generations. Samples from the 5th, 10th, 15th, 20th, 25th, and 30th passages were collected for PCR verification using the primers <italic toggle="yes">sptP</italic>-out-F and <italic toggle="yes">sptP</italic>-out-R, followed by sequencing to confirm genetic stability.</p></sec><sec id="sec2dot4-vaccines-13-00150"><title>2.4. The Ability of Bacteria to Invade Cells</title><p>Mouse macrophage RAW264.7 cells were grown in DMEM (high glucose) supplemented with 10% fetal bovine serum (FBS) and antibiotics (50 &#x000b5;g/mL penicillin). The cells were incubated at 37 &#x000b0;C in a humidified atmosphere of 5% CO<sub>2</sub> and 95% air. When the cells reached 90% confluence, ATCC14028 and ATCC14028&#x00394;<italic toggle="yes">sptP</italic> strains, which were normalized by OD<sub>600</sub>, at a multiplicity of infection (MOI) of 100:1 for 1 h.</p><p>After infection, extracellular bacteria were eliminated by washing the cells three times with PBS, followed by a 1 h incubation in DMEM containing 100 &#x000b5;g/mL gentamicin to eliminate residual extracellular bacteria. At designated post-infection time points (0, 2, 4, 8, 12, 24, and 48 h), the infected cells were washed three times with PBS and lysed with 1% Triton X-100 (wt/vol). The lysates were serially diluted, plated on MacConkey agar, and incubated at 37 &#x000b0;C for 12 h, after which colony-forming units (CFUs) were enumerated.</p></sec><sec id="sec2dot5-vaccines-13-00150"><title>2.5. Assessment of Bacterial Virulence</title><p>Female BALB/c mice, aged 4&#x02013;5 weeks, were housed under specific pathogen-free (SPF) conditions in our laboratory. All animal experiments were conducted in accordance with protocols approved by the Animal Protection and Ethics Committee of Hainan University (Haikou, China). To evaluate the virulence of ATCC14028&#x00394;<italic toggle="yes">sptP</italic> in mice, seventy mice were randomly assigned into fourteen groups, each comprising five mice. Each group was administered an intraperitoneal inoculation of ATCC14028&#x00394;<italic toggle="yes">sptP</italic> at one of ten serial dilutions, ranging from 1 &#x000d7; 10<sup>5</sup> to 1 &#x000d7; 10<sup>10</sup> CFUs, each in 200 &#x003bc;L of PBS. In a control experiment, ten additional mice were inoculated intraperitoneally with 200 &#x003bc;L of PBS. Mortality rates were recorded for each group at day 14 post-challenge. The median lethal dose (LD<sub>50</sub>) for the two strains was determined using the modified Cole method.</p></sec><sec id="sec2dot6-vaccines-13-00150"><title>2.6. Histopathological Tests</title><p>Surviving mice were humanely euthanized, and their livers and spleens were excised and immediately fixed in 4% paraformaldehyde. After fixation, tissue samples were processed for paraffin embedding, sectioned, stained with hematoxylin and eosin (H&#x00026;E), and subjected to histopathological evaluation under an optical microscope.</p></sec><sec id="sec2dot7-vaccines-13-00150"><title>2.7. Bacterial Invasion Ability Test</title><p>Seventy female BALB/c mice (4&#x02013;5 weeks old) were randomly allocated into three groups: the wild-type strain group, the &#x00394;<italic toggle="yes">sptP</italic> mutant group, and the PBS control group. Each mouse was injected intraperitoneally with 2 &#x000d7; 10<sup>4</sup> CFUs of the respective inoculum. On days 3, 6, 9, and 12 post-infection, mice were humanely euthanized, and liver, spleen, lung, and kidney samples were aseptically harvested. Tissue samples were homogenized using a high-throughput tissue homogenizer (KZ-III-FP, Wuhan Servicebio Biotechnology Co., Ltd., Wuhan, China) in sterile PBS. Homogenate dilutions were plated on McConkey agar and incubated at 37 &#x000b0;C for 12&#x02013;16 h to quantify CFUs.</p></sec><sec id="sec2dot8-vaccines-13-00150"><title>2.8. Immunoprotective Assessment of ATCC14028&#x00394;sptP</title><p>The immunoprotective effect of ATCC14028&#x00394;<italic toggle="yes">sptP</italic> in mice was assessed through intraperitoneal injections. Eighteen female BALB/c mice (4&#x02013;5 weeks old) were randomly divided into three groups (<italic toggle="yes">n</italic> = 6 per group): the immunized group, the non-immunized group, and the PBS control group. Mice in the immune group received an intraperitoneal injection of 2 &#x000d7; 10<sup>4</sup> CFUs of ATCC14028&#x00394;<italic toggle="yes">sptP</italic>, while the nonimmune and blank control groups were administered 200 &#x003bc;L of sterile PBS each. Two weeks post-initial immunization, booster doses were administered twice at one-week intervals. Following two weeks after the booster immunization, both the immunized and nonimmunized groups received an intraperitoneal injection of wild-type ATCC14028 at 10 times the LD<sub>50</sub> (5.01 &#x000d7; 10<sup>6</sup> CFUs), and the blank control group received 200 &#x003bc;L of PBS in a similar manner. Morbidity and survival rates were monitored for two weeks post-challenge, and liver and spleen tissues from surviving mice were collected for histopathological analysis.</p></sec><sec id="sec2dot9-vaccines-13-00150"><title>2.9. Serum IgG Assay</title><p>Mice were immunized via intraperitoneal injection following the procedure and dosage outlined in the immunoprotective efficacy evaluation. Blood samples were collected from the mice via retro-orbital puncture using capillary tubes, and serum was isolated through centrifugation. Changes in IgG levels were quantified using a mouse <italic toggle="yes">Salmonella</italic> IgG ELISA kit (Jiangsu Meimian Industrial Co., Ltd., Jiangsu, China) with absorbance measured at 492 nm.</p></sec><sec id="sec2dot10-vaccines-13-00150"><title>2.10. Data Analysis</title><p>Data analysis was conducted using GraphPad Prism 8 software (version 8.4.3). Data are presented as means &#x000b1; SEM. Within each group, an independent sample T-test was applied, while an analysis of variance for repeated measures (ANOVA) was used to compare means between groups. (* <italic toggle="yes">p</italic> &#x0003c; 0.05; ** <italic toggle="yes">p</italic> &#x0003c; 0.01; *** <italic toggle="yes">p</italic> &#x0003c; 0.001).</p></sec></sec><sec sec-type="results" id="sec3-vaccines-13-00150"><title>3. Results</title><sec id="sec3dot1-vaccines-13-00150"><title>3.1. Construction and Biological Characteristics of Mutant ATCC14028&#x00394;sptP</title><p>A mutant strain of <italic toggle="yes">Salmonella Typhimurium</italic> ATCC14028 with a disrupted <italic toggle="yes">sptP</italic> gene was generated through homologous recombination. PCR identification of ATCC14028&#x00394;<italic toggle="yes">sptP</italic>, performed using the <italic toggle="yes">sptP</italic>-cat-F/<italic toggle="yes">sptP</italic>-cat-R primers pair, confirmed the successful insertion of the chloramphenicol resistance gene into the <italic toggle="yes">sptP</italic> gene fragment. The mutant and wild-type strains were differentiated via PCR using flanking primers <italic toggle="yes">sptP</italic>-out-F and <italic toggle="yes">sptP</italic>-out-R. The presence of 1145 bp and 285 bp amplicons confirmed the successful construction of ATCC14028&#x00394;<italic toggle="yes">sptP</italic> (<xref rid="vaccines-13-00150-f001" ref-type="fig">Figure 1</xref>A). Additionally, the genetic stability and identity of the mutant were confirmed by DNA sequencing (<xref rid="app1-vaccines-13-00150" ref-type="app">Supplementary File, Figure S1A</xref>). Growth kinetics data indicated no statistically significant disparities in the growth rates of the mutant strain compared to the wild-type strain when cultivated at 37 &#x000b0;C in LB medium (<xref rid="vaccines-13-00150-f001" ref-type="fig">Figure 1</xref>B). Similarly, biochemical characterization showed no significant differences between the mutant and wild-type strains (<xref rid="app1-vaccines-13-00150" ref-type="app">Supplementary File, Table S1</xref>).</p></sec><sec id="sec3dot2-vaccines-13-00150"><title>3.2. Mutations in sptP Reduce Bacterial Invasion in Cells</title><p>Bacterial invasion in of RAW264.7 murine macrophages were quantified using a gentamicin protection assay. Quantitative analysis revealed that bacterial counts of ATCC14028&#x00394;<italic toggle="yes">sptP</italic> in cells were significantly lower than those of the wild-type strain at all time points during the infection (<xref rid="vaccines-13-00150-f002" ref-type="fig">Figure 2</xref>, <italic toggle="yes">p</italic> &#x02264; 0.001). These findings suggest that disruption of the <italic toggle="yes">sptP</italic> gene impairs the intracellular invasion capability of <italic toggle="yes">Salmonella Typhimurium</italic>.</p></sec><sec id="sec3dot3-vaccines-13-00150"><title>3.3. ATCC14028&#x00394;sptP Showed Reduced Virulence in Mice</title><p>To assess the virulence of ATCC14028&#x00394;<italic toggle="yes">sptP</italic> in mice, both ATCC14028&#x00394;<italic toggle="yes">sptP</italic> and the wild-type strain were administered intraperitoneally, and mouse survival was monitored. Analysis showed that the LD<sub>50</sub> of ATCC14028&#x00394;<italic toggle="yes">sptP</italic> was 2 &#x000d7; 10<sup>7</sup> CFUs, which is 40 times higher than that of the wild-type strain (5.01 &#x000d7; 10<sup>5</sup> CFUs). This indicates that disruption of the <italic toggle="yes">sptP</italic> gene significantly reduces the virulence of <italic toggle="yes">Salmonella Typhimurium</italic> (<xref rid="vaccines-13-00150-t002" ref-type="table">Table 2</xref>).</p></sec><sec id="sec3dot4-vaccines-13-00150"><title>3.4. ATCC14028&#x00394;sptP Showed Fewer Pathological Changes than Wild-Type Strains</title><p>H&#x00026;E staining and histological analysis of liver and spleen tissues from challenged mice revealed that, compared to the PBS control group, the wild-type group exhibited notably dilated hepatic veins with signs of congestion and hemorrhage, as well as a significant infiltration of inflammatory cells into the vessels and surrounding tissue. In the &#x00394;<italic toggle="yes">sptP</italic> group, there were minimal inflammatory cells, and no other lesions observed (<xref rid="vaccines-13-00150-f003" ref-type="fig">Figure 3</xref>A). Relative to the PBS control group, spleen nodules in the wild-type group were significantly enlarged, accompanied by extensive inflammatory cell exudation and bleeding. The &#x00394;<italic toggle="yes">sptP</italic> group exhibited milder symptoms, characterized by slight enlargement of splenic nodules, minimal inflammatory cell exudation, and no additional lesions (<xref rid="vaccines-13-00150-f003" ref-type="fig">Figure 3</xref>B). Collectively, these findings suggest that the <italic toggle="yes">sptP</italic> mutation in <italic toggle="yes">Salmonella Typhimurium</italic> results in a more attenuated disease phenotype in infected mice.</p></sec><sec id="sec3dot5-vaccines-13-00150"><title>3.5. The Invasion Capacity of ATCC14028&#x00394;sptP in Mouse Visceral Tissues Was Reduced Compared to the Wild-Type Strain</title><p>The CFUs counts in the liver, spleen, lungs, and kidneys of mice were determined following injection with ATCC14028&#x00394;<italic toggle="yes">sptP</italic> and the wild-type ATCC14028 strain. In the third day post-injection, ATCC14028&#x00394;<italic toggle="yes">sptP</italic> exhibited a decreasing trend in organ invasion, in contrast to the increasing trend observed in wild-type strains. The replication of ATCC14028&#x00394;<italic toggle="yes">sptP</italic> peaked on day 6 post-injection and then declined. Notably, the clearance rate of ATCC14028&#x00394;<italic toggle="yes">sptP</italic> within the first three days was significantly higher compared to wild-type strains, and its peak invasion level on the sixth day was lower than that observed in wild-type strains.</p><p>Interestingly, on the sixth day post-injection, the CFU counts for both the mutant and wild-type strains were more similar in liver and lung tissues compared to spleen and kidney tissues. Specifically, while the wild-type strain maintained a higher bacterial load in all organs, the difference in CFU counts between the mutant and wild-type strains was less pronounced in the liver and lungs relative to the spleen and kidneys. This suggests that the <italic toggle="yes">sptP</italic> gene mutation has a differential impact on bacterial survival and replication across different host tissues. These findings demonstrate that the <italic toggle="yes">sptP</italic> gene mutation significantly diminishes the infection and invasion capabilities of <italic toggle="yes">Salmonella Typhimurium</italic> in mice (<xref rid="vaccines-13-00150-f004" ref-type="fig">Figure 4</xref>). The reduced ability of the ATCC14028&#x00394;<italic toggle="yes">sptP</italic> to persist in major organs highlights the critical role of the <italic toggle="yes">sptP</italic> gene in facilitating systemic infection and tissue-specific colonization.</p></sec><sec id="sec3dot6-vaccines-13-00150"><title>3.6. ATCC14028&#x00394;sptP Protects Mice Against Wild-Type Salmonella Typhimurium</title><p>Following two immunizations with ATCC14028&#x00394;<italic toggle="yes">sptP</italic>, the survival rates of mice after challenge with virulent strains are presented in <xref rid="vaccines-13-00150-f005" ref-type="fig">Figure 5</xref>C. In the PBS control group, mortalities were observed on days 5, 8, 10, and 12 post-infection (DPI). Two additional deaths occurred on day 9 DPI in the PBS control group following challenge with the wild-type strain. One death was recorded on day 7 DPI in the ATCC14028&#x00394;<italic toggle="yes">sptP</italic>-immunized group. These results indicate that immunization with the &#x00394;<italic toggle="yes">sptP</italic> strain of <italic toggle="yes">Salmonella Typhimurium</italic> significantly protects against subsequent challenge with virulent strains, achieving an 87.5% protection rate. At the end of the experiment, only one mouse survived in the wild-type strain group inoculated with 1 &#x000d7; 10<sup>6</sup> CFUs, making the sample size too small for meaningful statistical analysis and pathological observation. Therefore, to ensure a sufficient sample size and reliable results, we chose to perform histopathological examinations on surviving mice from the 1 &#x000d7; 10<sup>5</sup> CFUs concentration groups for both the wild-type and mutant strains. Histopathological evaluation revealed that, compared to the PBS control group, the wild-type group exhibited dilated hepatic veins, markedly enlarged splenic nodules, and a significant presence of inflammatory cells within blood vessels. In contrast, the ATCC14028&#x00394;<italic toggle="yes">sptP</italic> group showed no significant histopathological alterations (<xref rid="vaccines-13-00150-f005" ref-type="fig">Figure 5</xref>A,B).</p></sec><sec id="sec3dot7-vaccines-13-00150"><title>3.7. The ATCC14028&#x00394;sptP Strain Induced an Immune Response Similar to That of the Wild-Type Strain</title><p>IgG levels in mice were measured following immunization (<xref rid="vaccines-13-00150-f005" ref-type="fig">Figure 5</xref>D). In the first and second weeks post-initial immunization, there were no significant differences in IgG levels between the ATCC14028&#x00394;<italic toggle="yes">sptP</italic> and wild-type groups compared to the PBS control group. However, after booster immunizations, IgG levels significantly increased in both the &#x00394;<italic toggle="yes">sptP</italic> strain and wild-type groups, with no substantial difference between them. These findings suggested that the &#x00394;<italic toggle="yes">sptP</italic> strain of <italic toggle="yes">Salmonella Typhimurium</italic> can elicit an immune response comparable to that induced by the wild-type strain.</p></sec></sec><sec sec-type="discussion" id="sec4-vaccines-13-00150"><title>4. Discussion</title><p><italic toggle="yes">Salmonella Typhimurium</italic>, a prevalent intestinal pathogen, is recognized for causing a range of gastrointestinal illnesses in both animals and humans, which can result in persistent infections and subsequently lead to systemic symptoms and tissue damage [<xref rid="B25-vaccines-13-00150" ref-type="bibr">25</xref>,<xref rid="B26-vaccines-13-00150" ref-type="bibr">26</xref>,<xref rid="B27-vaccines-13-00150" ref-type="bibr">27</xref>]. Given the rising antibiotic resistance in <italic toggle="yes">Salmonella</italic> spp. and the lack of new antibiotics [<xref rid="B28-vaccines-13-00150" ref-type="bibr">28</xref>], attenuated <italic toggle="yes">Salmonella</italic> strains provide an ideal vaccine strategy for infection control and prevention. Multiple live attenuated vaccines against Salmonella have been developed, showing greater efficacy than inactivated vaccines [<xref rid="B29-vaccines-13-00150" ref-type="bibr">29</xref>]. Attenuated <italic toggle="yes">Salmonella Typhimurium</italic> strains can reduce or eliminate virulence by various means of knocking out virulence genes, but these strains possess inherent shortcomings, such as the potential reversion to pathogenicity due to gene repair, thus limiting the clinical use of such live attenuated vaccines [<xref rid="B30-vaccines-13-00150" ref-type="bibr">30</xref>].</p><p>In this study, we successfully engineered a mutant strain of <italic toggle="yes">Salmonella Typhimurium</italic> ATCC14028&#x00394;<italic toggle="yes">sptP</italic> using homologous recombination. Vaccine strains require a well-defined genetic background and genetic stability, which are critical for developing effective attenuated vaccines. The &#x00394;<italic toggle="yes">sptP</italic> mutant strain maintained the <italic toggle="yes">sptP</italic> gene mutation stably over 30 consecutive generations. Moreover, we verified that mutating the <italic toggle="yes">sptP</italic> gene did not significantly affect colony morphology, biochemical characteristics, or growth rate, likely due to its acquisition through horizontal gene transfer linked to SPI-1 [<xref rid="B31-vaccines-13-00150" ref-type="bibr">31</xref>]. These findings support the potential of the <italic toggle="yes">sptP</italic> gene as a target for live attenuated vaccine development.</p><p>We subsequently evaluated the &#x00394;<italic toggle="yes">sptP</italic> mutants for safety, serum immunoglobulin levels, and protective efficacy, revealing the <italic toggle="yes">sptP</italic> gene&#x02019;s critical role in <italic toggle="yes">Salmonella Typhimurium</italic> pathogenicity and providing robust evidence for the potential of ATCC14028&#x00394;<italic toggle="yes">sptP</italic> as an effective live attenuated vaccine against <italic toggle="yes">Salmonella Typhimurium</italic> infections. Although oral vaccination can mimic the practical application of vaccines in livestock and humans, we opted for intraperitoneal injection primarily due to the following considerations: Firstly, intraperitoneal injection allows for precise control over the vaccine dose&#x02019;s accuracy and consistency, crucial for initial safety and immunogenicity assessments [<xref rid="B32-vaccines-13-00150" ref-type="bibr">32</xref>,<xref rid="B33-vaccines-13-00150" ref-type="bibr">33</xref>]. Secondly, this approach avoids confounding factors from the digestive tract during the initial stages, enabling the collection of direct and unobstructed immune response data. Literature also indicates that in the initial evaluation stage of vaccines, non-oral routes are a common practice, especially for exploring the basic immunogenicity and efficacy of vaccines [<xref rid="B33-vaccines-13-00150" ref-type="bibr">33</xref>,<xref rid="B34-vaccines-13-00150" ref-type="bibr">34</xref>,<xref rid="B35-vaccines-13-00150" ref-type="bibr">35</xref>]. Although oral administration is closer to the actual application scenario of the vaccine, the current research aims to confirm the core safety and immune effect of the vaccine by intraperitoneal injection, avoiding the complex variables that may be introduced by digestive enzymes, mucosal barrier variability, and other factors in the early stage. Once the vaccine&#x02019;s basic immunogenicity and safety are established, our research will transition smoothly to the oral route to simulate vaccine application accurately in the target species. This step-by-step strategy not only ensures systematic and phased research, but also follows the traditional path of vaccine research and development [<xref rid="B36-vaccines-13-00150" ref-type="bibr">36</xref>,<xref rid="B37-vaccines-13-00150" ref-type="bibr">37</xref>].</p><p>Our findings revealed that mutating the <italic toggle="yes">sptP</italic> gene in <italic toggle="yes">Salmonella Typhimurium</italic> significantly reduced bacterial viability in the mutant strain relative to the wild-type strain during infection of RAW264.7 macrophages. This reduction was particularly evident in the early stages of infection, indicating that <italic toggle="yes">sptP</italic> plays a crucial role in facilitating bacterial entry into host cells during the initial infection phase. Moreover, the ability of the &#x00394;<italic toggle="yes">sptP</italic> mutant strain to colonize organs in mice was markedly diminished. These findings suggest that <italic toggle="yes">sptP</italic> effector molecules play a key role in enhancing the invasion capabilities of <italic toggle="yes">Salmonella Typhimurium</italic> into host cells. Essential characteristics of live attenuated vaccines include safety and non-toxicity.</p><p>In our study, after intraperitoneal administration of the &#x00394;<italic toggle="yes">sptP</italic> mutant and wild-type strains to separate groups of BALB/c mice, we found that the calculated LD<sub>50</sub> value of the &#x00394;<italic toggle="yes">sptP</italic> mutant strain was found to be 39.92-fold higher than that of the wild-type strain. This indicates a significant reduction in the virulence of the &#x00394;<italic toggle="yes">sptP</italic> mutant. In addition to attenuation, it is crucial for live attenuated vaccines to exhibit no adverse effects on host animals. Immunization with the &#x00394;<italic toggle="yes">sptP</italic> mutant resulted in only minor histopathological changes in the inoculated mice. Concurrently, the wild-type strain induced significant infiltration of inflammatory cells into the liver and spleen, along with symptoms of congestion, demonstrating that the mutant is sufficiently safe and attenuated for use as a live vaccine.</p><p>In the context of live attenuated vaccines, immune protection is a pivotal criterion for evaluating vaccine efficacy. Consequently, live attenuated vaccines effectively elicit host-specific humoral and cellular immune responses, which are critical for preventing secondary infections by pathogens [<xref rid="B38-vaccines-13-00150" ref-type="bibr">38</xref>]. After immunization with the &#x00394;<italic toggle="yes">sptP</italic> mutant strain, serum IgG levels measured on days 21 and 28 were comparable to those induced by the wild-type strain and significantly higher than those in the PBS control group. Furthermore, the &#x00394;<italic toggle="yes">sptP</italic> mutant strain provides up to 87.5% immune protection against a virulent strain of <italic toggle="yes">Salmonella Typhimurium</italic>. Mice immunized with the &#x00394;<italic toggle="yes">sptP</italic> mutant strain exhibited no significant pathological changes in the liver and spleen post-infection with the wild-type strain, unlike those in the PBS control group. Therefore, while the virulence of <italic toggle="yes">Salmonella Typhimurium</italic> is attenuated following the <italic toggle="yes">sptP</italic> gene mutation, it maintains commendable immunogenicity, enabling it to confer a robust level of both humoral and cellular immunity and protect the host.</p><p>Given the potential real-world applications of this vaccine, it is crucial to approach its associated risks cautiously. Firstly, although our studies have demonstrated that the &#x00394;<italic toggle="yes">sptP</italic> mutant exhibits reduced virulence and genetic stability under laboratory conditions, these characteristics may differ in complex natural environments. Long-term monitoring of the vaccine strain is essential to ensure its safety, especially when evaluating its performance across diverse host populations. Different types of animals may exhibit varied immune responses to the same vaccine [<xref rid="B17-vaccines-13-00150" ref-type="bibr">17</xref>]. Additionally, considering the potential for live vaccine strains to spread in the environment, it is imperative to carefully assess the impact of such dissemination on ecosystems and wildlife populations [<xref rid="B39-vaccines-13-00150" ref-type="bibr">39</xref>]. Implementing appropriate measures, such as optimizing administration methods and dosages, to limit exposure to non-target species is crucial for maintaining ecological balance.</p><p>Overall, this study provides a robust theoretical foundation for the development of an attenuated live vaccine for <italic toggle="yes">Salmonella Typhimurium</italic>. Future work will continue to focus on enhancing the safety and efficacy of the vaccine, aiming to provide a safe and effective solution for preventing <italic toggle="yes">Salmonella Typhimurium</italic> infections.</p></sec><sec sec-type="conclusions" id="sec5-vaccines-13-00150"><title>5. Conclusions</title><p>In summary, we successfully engineered a mutant strain of <italic toggle="yes">Salmonella Typhimurium</italic> with a &#x00394;<italic toggle="yes">sptP</italic> gene deletion. Experimental results showed that the invasive capability and overall virulence of <italic toggle="yes">Salmonella Typhimurium</italic> were significantly reduced following the <italic toggle="yes">sptP</italic> gene mutation. Moreover, the &#x00394;<italic toggle="yes">sptP</italic> mutant elicited strong immunogenic responses and provided robust immune protection in mice, indicating its potential as an effective live attenuated vaccine against <italic toggle="yes">Salmonella Typhimurium</italic>. These findings lay a solid theoretical foundation for further exploring and developing live attenuated vaccines.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors would like to thank all the colleagues who provided practical and theoretical help and the teachers who provided instrumentation and experimental guidance.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-vaccines-13-00150"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xlink:href="https://www.mdpi.com/article/10.3390/vaccines13020150/s1">https://www.mdpi.com/article/10.3390/vaccines13020150/s1</uri>, Figure S1. Biological characteristic test of ATCC14028&#x00394;<italic toggle="yes">sptP</italic>. (<bold>A</bold>) Genetic stability of ATCC14028&#x00394;<italic toggle="yes">sptP</italic>. (<bold>B</bold>) Colony morphology of ATCC14028&#x00394;<italic toggle="yes">sptP</italic> (a) and ATCC14028 (b); Table S1. Biochemical properties of <italic toggle="yes">Salmonella Typhimurium</italic> ATCC14028 and ATCC14028&#x00394;<italic toggle="yes">sptP</italic>.</p><supplementary-material id="vaccines-13-00150-s001" position="float" content-type="local-data"><media xlink:href="vaccines-13-00150-s001.zip"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>T.L. and M.H. conceived and designed the experiment and drafted the manuscript; N.Z. and Y.D. contributed to the realization of the experiment; T.H., H.C. and Y.S. analyzed the data and helped with the experiments; N.Z., T.H. and Y.D. wrote the manuscript. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>All animal experiments were approved by the Animal Ethics Committee of Hainan University (Approval Code: HNUAUCC-2023-00213, approval date: 15 December 2023) and comply with all moral and ethical requirements.</p></notes><notes><title>Informed Consent Statement</title><p>Informed consent was obtained from all subjects involved in the study.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-vaccines-13-00150"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Branchu</surname><given-names>P.</given-names></name>
<name><surname>Bawn</surname><given-names>M.</given-names></name>
<name><surname>Kingsley</surname><given-names>R.A.</given-names></name>
</person-group><article-title>Genome Variation and Molecular Epidemiology of <italic toggle="yes">Salmonella</italic> Enterica Serovar <italic toggle="yes">Typhimurium</italic> Pathovariants</article-title><source>Infect. Immun.</source><year>2018</year><volume>86</volume><fpage>e00079-18</fpage><pub-id pub-id-type="doi">10.1128/IAI.00079-18</pub-id><pub-id pub-id-type="pmid">29784861</pub-id>
</element-citation></ref><ref id="B2-vaccines-13-00150"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>F&#x000e0;brega</surname><given-names>A.</given-names></name>
<name><surname>Vila</surname><given-names>J.</given-names></name>
</person-group><article-title><italic toggle="yes">Salmonella</italic> Enterica Serovar <italic toggle="yes">Typhimurium</italic> Skills to Succeed in the Host: Virulence and Regulation</article-title><source>Clin. Microbiol. Rev.</source><year>2013</year><volume>26</volume><fpage>308</fpage><lpage>341</lpage><pub-id pub-id-type="doi">10.1128/CMR.00066-12</pub-id><pub-id pub-id-type="pmid">23554419</pub-id>
</element-citation></ref><ref id="B3-vaccines-13-00150"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Broz</surname><given-names>P.</given-names></name>
<name><surname>Ohlson</surname><given-names>M.B.</given-names></name>
<name><surname>Monack</surname><given-names>D.M.</given-names></name>
</person-group><article-title>Innate Immune Response to <italic toggle="yes">Salmonella typhimurium</italic>, a Model Enteric Pathogen</article-title><source>Gut Microbes</source><year>2012</year><volume>3</volume><fpage>62</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.4161/gmic.19141</pub-id><pub-id pub-id-type="pmid">22198618</pub-id>
</element-citation></ref><ref id="B4-vaccines-13-00150"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>M&#x000e9;nard</surname><given-names>S.</given-names></name>
<name><surname>Lacroix-Lamand&#x000e9;</surname><given-names>S.</given-names></name>
<name><surname>Ehrhardt</surname><given-names>K.</given-names></name>
<name><surname>Yan</surname><given-names>J.</given-names></name>
<name><surname>Grassl</surname><given-names>G.A.</given-names></name>
<name><surname>Wiedemann</surname><given-names>A.</given-names></name>
</person-group><article-title>Cross-Talk Between the Intestinal Epithelium and <italic toggle="yes">Salmonella</italic> Typhimurium</article-title><source>Front. Microbiol.</source><year>2022</year><volume>13</volume><elocation-id>906238</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2022.906238</pub-id><pub-id pub-id-type="pmid">35733975</pub-id>
</element-citation></ref><ref id="B5-vaccines-13-00150"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jiang</surname><given-names>L.</given-names></name>
<name><surname>Wang</surname><given-names>P.</given-names></name>
<name><surname>Song</surname><given-names>X.</given-names></name>
<name><surname>Zhang</surname><given-names>H.</given-names></name>
<name><surname>Ma</surname><given-names>S.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Li</surname><given-names>W.</given-names></name>
<name><surname>Lv</surname><given-names>R.</given-names></name>
<name><surname>Liu</surname><given-names>X.</given-names></name>
<name><surname>Ma</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title><italic toggle="yes">Salmonella</italic> Typhimurium Reprograms Macrophage Metabolism via T3SS Effector SopE2 to Promote Intracellular Replication and Virulence</article-title><source>Nat. Commun.</source><year>2021</year><volume>12</volume><fpage>879</fpage><pub-id pub-id-type="doi">10.1038/s41467-021-21186-4</pub-id><pub-id pub-id-type="pmid">33563986</pub-id>
</element-citation></ref><ref id="B6-vaccines-13-00150"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>Q.</given-names></name>
<name><surname>Li</surname><given-names>P.</given-names></name>
<name><surname>Luo</surname><given-names>H.</given-names></name>
<name><surname>Curtiss</surname><given-names>R.</given-names></name>
<name><surname>Kong</surname><given-names>Q.</given-names></name>
</person-group><article-title>Attenuated <italic toggle="yes">Salmonella</italic> Typhimurium Expressing <italic toggle="yes">Salmonella</italic> Paratyphoid A O-Antigen Induces Protective Immune Responses against Two <italic toggle="yes">Salmonella</italic> Strains</article-title><source>Virulence</source><year>2019</year><volume>10</volume><fpage>82</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1080/21505594.2018.1559673</pub-id><pub-id pub-id-type="pmid">31874075</pub-id>
</element-citation></ref><ref id="B7-vaccines-13-00150"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Beuz&#x000f3;n</surname><given-names>C.R.</given-names></name>
<name><surname>M&#x000e9;resse</surname><given-names>S.</given-names></name>
<name><surname>Unsworth</surname><given-names>K.E.</given-names></name>
<name><surname>Ru&#x000ed;z-Albert</surname><given-names>J.</given-names></name>
<name><surname>Garvis</surname><given-names>S.</given-names></name>
<name><surname>Waterman</surname><given-names>S.R.</given-names></name>
<name><surname>Ryder</surname><given-names>T.A.</given-names></name>
<name><surname>Boucrot</surname><given-names>E.</given-names></name>
<name><surname>Holden</surname><given-names>D.W.</given-names></name>
</person-group><article-title><italic toggle="yes">Salmonella</italic> Maintains the Integrity of Its Intracellular Vacuole through the Action of SifA</article-title><source>EMBO J.</source><year>2000</year><volume>19</volume><fpage>3235</fpage><lpage>3249</lpage><pub-id pub-id-type="doi">10.1093/emboj/19.13.3235</pub-id><pub-id pub-id-type="pmid">10880437</pub-id>
</element-citation></ref><ref id="B8-vaccines-13-00150"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Luk</surname><given-names>C.H.</given-names></name>
<name><surname>Enninga</surname><given-names>J.</given-names></name>
<name><surname>Valenzuela</surname><given-names>C.</given-names></name>
</person-group><article-title>Fit to Dwell in Many Places&#x02014;The Growing Diversity of Intracellular <italic toggle="yes">Salmonella</italic> Niches</article-title><source>Front. Cell Infect. Microbiol.</source><year>2022</year><volume>12</volume><elocation-id>989451</elocation-id><pub-id pub-id-type="doi">10.3389/fcimb.2022.989451</pub-id><pub-id pub-id-type="pmid">36061869</pub-id>
</element-citation></ref><ref id="B9-vaccines-13-00150"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>B&#x000e4;umler</surname><given-names>A.J.</given-names></name>
<name><surname>Tsolis</surname><given-names>R.M.</given-names></name>
<name><surname>Heffron</surname><given-names>F.</given-names></name>
</person-group><article-title>Contribution of Fimbrial Operons to Attachment to and Invasion of Epithelial Cell Lines by Salmonella Typhimurium</article-title><source>Infect. Immun.</source><year>1996</year><volume>64</volume><fpage>1862</fpage><lpage>1865</lpage><pub-id pub-id-type="doi">10.1128/iai.64.5.1862-1865.1996</pub-id><pub-id pub-id-type="pmid">8613405</pub-id>
</element-citation></ref><ref id="B10-vaccines-13-00150"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hapfelmeier</surname><given-names>S.</given-names></name>
<name><surname>Stecher</surname><given-names>B.</given-names></name>
<name><surname>Barthel</surname><given-names>M.</given-names></name>
<name><surname>Kremer</surname><given-names>M.</given-names></name>
<name><surname>M&#x000fc;ller</surname><given-names>A.J.</given-names></name>
<name><surname>Heikenwalder</surname><given-names>M.</given-names></name>
<name><surname>Stallmach</surname><given-names>T.</given-names></name>
<name><surname>Hensel</surname><given-names>M.</given-names></name>
<name><surname>Pfeffer</surname><given-names>K.</given-names></name>
<name><surname>Akira</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>The <italic toggle="yes">Salmonella</italic> Pathogenicity Island (SPI)-2 and SPI-1 Type III Secretion Systems Allow <italic toggle="yes">Salmonella</italic> Serovar <italic toggle="yes">Typhimurium</italic> to Trigger Colitis via MyD88-Dependent and MyD88-Independent Mechanisms</article-title><source>J. Immunol.</source><year>2005</year><volume>174</volume><fpage>1675</fpage><lpage>1685</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.174.3.1675</pub-id><pub-id pub-id-type="pmid">15661931</pub-id>
</element-citation></ref><ref id="B11-vaccines-13-00150"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Siriken</surname><given-names>B.</given-names></name>
</person-group><article-title><italic toggle="yes">Salmonella</italic> Pathogenicity Islands</article-title><source>Mikrobiyol. Bul.</source><year>2013</year><volume>47</volume><fpage>181</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.5578/mb.4138</pub-id><pub-id pub-id-type="pmid">23390917</pub-id>
</element-citation></ref><ref id="B12-vaccines-13-00150"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jennings</surname><given-names>E.</given-names></name>
<name><surname>Thurston</surname><given-names>T.L.M.</given-names></name>
<name><surname>Holden</surname><given-names>D.W.</given-names></name>
</person-group><article-title><italic toggle="yes">Salmonella</italic> SPI-2 Type III Secretion System Effectors: Molecular Mechanisms and Physiological Consequences</article-title><source>Cell Host Microbe</source><year>2017</year><volume>22</volume><fpage>217</fpage><lpage>231</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2017.07.009</pub-id><pub-id pub-id-type="pmid">28799907</pub-id>
</element-citation></ref><ref id="B13-vaccines-13-00150"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Siceloff</surname><given-names>A.T.</given-names></name>
<name><surname>Ohta</surname><given-names>N.</given-names></name>
<name><surname>Norman</surname><given-names>K.N.</given-names></name>
<name><surname>Loneragan</surname><given-names>G.H.</given-names></name>
<name><surname>Norby</surname><given-names>B.</given-names></name>
<name><surname>Scott</surname><given-names>H.M.</given-names></name>
<name><surname>Shariat</surname><given-names>N.W.</given-names></name>
</person-group><article-title>Antimicrobial Resistance Hidden within Multiserovar <italic toggle="yes">Salmonella</italic> Populations</article-title><source>Antimicrob. Agents Chemother.</source><year>2021</year><volume>65</volume><fpage>e00048-21</fpage><pub-id pub-id-type="doi">10.1128/AAC.00048-21</pub-id><pub-id pub-id-type="pmid">33782004</pub-id>
</element-citation></ref><ref id="B14-vaccines-13-00150"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pulford</surname><given-names>C.V.</given-names></name>
<name><surname>Perez-Sepulveda</surname><given-names>B.M.</given-names></name>
<name><surname>Canals</surname><given-names>R.</given-names></name>
<name><surname>Bevington</surname><given-names>J.A.</given-names></name>
<name><surname>Bengtsson</surname><given-names>R.J.</given-names></name>
<name><surname>Wenner</surname><given-names>N.</given-names></name>
<name><surname>Rodwell</surname><given-names>E.V.</given-names></name>
<name><surname>Kumwenda</surname><given-names>B.</given-names></name>
<name><surname>Zhu</surname><given-names>X.</given-names></name>
<name><surname>Bennett</surname><given-names>R.J.</given-names></name>
<etal/>
</person-group><article-title>Stepwise Evolution of <italic toggle="yes">Salmonella</italic> Typhimurium ST313 Causing Bloodstream Infection in Africa</article-title><source>Nat. Microbiol.</source><year>2021</year><volume>6</volume><fpage>327</fpage><lpage>338</lpage><pub-id pub-id-type="doi">10.1038/s41564-020-00836-1</pub-id><pub-id pub-id-type="pmid">33349664</pub-id>
</element-citation></ref><ref id="B15-vaccines-13-00150"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhao</surname><given-names>X.</given-names></name>
<name><surname>Ju</surname><given-names>Z.</given-names></name>
<name><surname>Wang</surname><given-names>G.</given-names></name>
<name><surname>Yang</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>F.</given-names></name>
<name><surname>Tang</surname><given-names>H.</given-names></name>
<name><surname>Zhao</surname><given-names>X.</given-names></name>
<name><surname>Sun</surname><given-names>S.</given-names></name>
</person-group><article-title>Prevalence and Antimicrobial Resistance of <italic toggle="yes">Salmonella</italic> Isolated from Dead-in-Shell Chicken Embryos in Shandong, China</article-title><source>Front. Vet. Sci.</source><year>2021</year><volume>8</volume><elocation-id>581946</elocation-id><pub-id pub-id-type="doi">10.3389/fvets.2021.581946</pub-id><pub-id pub-id-type="pmid">33796577</pub-id>
</element-citation></ref><ref id="B16-vaccines-13-00150"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sears</surname><given-names>K.T.</given-names></name>
<name><surname>Galen</surname><given-names>J.E.</given-names></name>
<name><surname>Tennant</surname><given-names>S.M.</given-names></name>
</person-group><article-title>Advances in the Development of <italic toggle="yes">Salmonella</italic>-Based Vaccine Strategies for Protection against Salmonellosis in Humans</article-title><source>J. Appl. Microbiol.</source><year>2021</year><volume>131</volume><fpage>2640</fpage><lpage>2658</lpage><pub-id pub-id-type="doi">10.1111/jam.15055</pub-id><pub-id pub-id-type="pmid">33665941</pub-id>
</element-citation></ref><ref id="B17-vaccines-13-00150"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tennant</surname><given-names>S.M.</given-names></name>
<name><surname>Levine</surname><given-names>M.M.</given-names></name>
</person-group><article-title>Live Attenuated Vaccines for Invasive <italic toggle="yes">Salmonella</italic> Infections</article-title><source>Vaccine</source><year>2015</year><volume>33</volume><fpage>C36</fpage><lpage>C41</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2015.04.029</pub-id><pub-id pub-id-type="pmid">25902362</pub-id>
</element-citation></ref><ref id="B18-vaccines-13-00150"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jung</surname><given-names>B.</given-names></name>
<name><surname>Park</surname><given-names>S.</given-names></name>
<name><surname>Kim</surname><given-names>E.</given-names></name>
<name><surname>Yoon</surname><given-names>H.</given-names></name>
<name><surname>Hahn</surname><given-names>T.-W.</given-names></name>
</person-group><article-title><italic toggle="yes">Salmonella</italic> Typhimurium Lacking phoBR as a Live Vaccine Candidate against Poultry Infection</article-title><source>Vet. Microbiol.</source><year>2022</year><volume>266</volume><elocation-id>109342</elocation-id><pub-id pub-id-type="doi">10.1016/j.vetmic.2022.109342</pub-id><pub-id pub-id-type="pmid">35063827</pub-id>
</element-citation></ref><ref id="B19-vaccines-13-00150"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Park</surname><given-names>S.</given-names></name>
<name><surname>Jung</surname><given-names>B.</given-names></name>
<name><surname>Kim</surname><given-names>E.</given-names></name>
<name><surname>Hong</surname><given-names>S.-T.</given-names></name>
<name><surname>Yoon</surname><given-names>H.</given-names></name>
<name><surname>Hahn</surname><given-names>T.-W.</given-names></name>
</person-group><article-title><italic toggle="yes">Salmonella</italic> Typhimurium Lacking YjeK as a Candidate Live Attenuated Vaccine Against Invasive <italic toggle="yes">Salmonella</italic> Infection</article-title><source>Front. Immunol.</source><year>2020</year><volume>11</volume><elocation-id>1277</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2020.01277</pub-id><pub-id pub-id-type="pmid">32655567</pub-id>
</element-citation></ref><ref id="B20-vaccines-13-00150"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lin</surname><given-names>Z.</given-names></name>
<name><surname>Tang</surname><given-names>P.</given-names></name>
<name><surname>Jiao</surname><given-names>Y.</given-names></name>
<name><surname>Kang</surname><given-names>X.</given-names></name>
<name><surname>Li</surname><given-names>Q.</given-names></name>
<name><surname>Xu</surname><given-names>X.</given-names></name>
<name><surname>Sun</surname><given-names>J.</given-names></name>
<name><surname>Pan</surname><given-names>Z.</given-names></name>
<name><surname>Jiao</surname><given-names>X.</given-names></name>
</person-group><article-title>Immunogenicity and Protective Efficacy of a <italic toggle="yes">Salmonella</italic> Enteritidis <italic toggle="yes">sptP</italic> Mutant as a Live Attenuated Vaccine Candidate</article-title><source>BMC Vet. Res.</source><year>2017</year><volume>13</volume><elocation-id>194</elocation-id><pub-id pub-id-type="doi">10.1186/s12917-017-1115-3</pub-id><pub-id pub-id-type="pmid">28646853</pub-id>
</element-citation></ref><ref id="B21-vaccines-13-00150"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Johnson</surname><given-names>R.</given-names></name>
<name><surname>Byrne</surname><given-names>A.</given-names></name>
<name><surname>Berger</surname><given-names>C.N.</given-names></name>
<name><surname>Klemm</surname><given-names>E.</given-names></name>
<name><surname>Crepin</surname><given-names>V.F.</given-names></name>
<name><surname>Dougan</surname><given-names>G.</given-names></name>
<name><surname>Frankel</surname><given-names>G.</given-names></name>
</person-group><article-title>The Type III Secretion System Effector SptP of <italic toggle="yes">Salmonella</italic> Enterica Serovar Typhi</article-title><source>J. Bacteriol.</source><year>2017</year><volume>199</volume><fpage>e00647-16</fpage><pub-id pub-id-type="doi">10.1128/JB.00647-16</pub-id><pub-id pub-id-type="pmid">27920299</pub-id>
</element-citation></ref><ref id="B22-vaccines-13-00150"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fu</surname><given-names>Y.</given-names></name>
<name><surname>Gal&#x000e1;n</surname><given-names>J.E.</given-names></name>
</person-group><article-title>The <italic toggle="yes">Salmonella typhimurium</italic> Tyrosine Phosphatase SptP Is Translocated into Host Cells and Disrupts the Actin Cytoskeleton</article-title><source>Mol. Microbiol.</source><year>1998</year><volume>27</volume><fpage>359</fpage><lpage>368</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2958.1998.00684.x</pub-id><pub-id pub-id-type="pmid">9484891</pub-id>
</element-citation></ref><ref id="B23-vaccines-13-00150"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhou</surname><given-names>D.</given-names></name>
<name><surname>Gal&#x000e1;n</surname><given-names>J.</given-names></name>
</person-group><article-title><italic toggle="yes">Salmonella</italic> Entry into Host Cells: The Work in Concert of Type III Secreted Effector Proteins</article-title><source>Microbes Infect.</source><year>2001</year><volume>3</volume><fpage>1293</fpage><lpage>1298</lpage><pub-id pub-id-type="doi">10.1016/S1286-4579(01)01489-7</pub-id><pub-id pub-id-type="pmid">11755417</pub-id>
</element-citation></ref><ref id="B24-vaccines-13-00150"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stebbins</surname><given-names>C.E.</given-names></name>
<name><surname>Gal&#x000e1;n</surname><given-names>J.E.</given-names></name>
</person-group><article-title>Modulation of Host Signaling by a Bacterial Mimic: Structure of the <italic toggle="yes">Salmonella</italic> Effector SptP Bound to Rac1</article-title><source>Mol. Cell</source><year>2000</year><volume>6</volume><fpage>1449</fpage><lpage>1460</lpage><pub-id pub-id-type="doi">10.1016/S1097-2765(00)00141-6</pub-id><pub-id pub-id-type="pmid">11163217</pub-id>
</element-citation></ref><ref id="B25-vaccines-13-00150"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gal&#x000e1;n</surname><given-names>J.E.</given-names></name>
</person-group><article-title><italic toggle="yes">Salmonella</italic> Typhimurium and Inflammation: A Pathogen-Centric Affair</article-title><source>Nat. Rev. Microbiol.</source><year>2021</year><volume>19</volume><fpage>716</fpage><lpage>725</lpage><pub-id pub-id-type="doi">10.1038/s41579-021-00561-4</pub-id><pub-id pub-id-type="pmid">34012042</pub-id>
</element-citation></ref><ref id="B26-vaccines-13-00150"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>S.</given-names></name>
<name><surname>Zhang</surname><given-names>C.</given-names></name>
<name><surname>Liao</surname><given-names>C.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Yu</surname><given-names>C.</given-names></name>
<name><surname>Cheng</surname><given-names>X.</given-names></name>
<name><surname>Yu</surname><given-names>Z.</given-names></name>
<name><surname>Zhang</surname><given-names>M.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
</person-group><article-title>Deletion of Invasion Protein B in <italic toggle="yes">Salmonella</italic> Enterica Serovar <italic toggle="yes">Typhimurium</italic> Influences Bacterial Invasion and Virulence</article-title><source>Curr. Microbiol.</source><year>2015</year><volume>71</volume><fpage>687</fpage><lpage>692</lpage><pub-id pub-id-type="doi">10.1007/s00284-015-0903-x</pub-id><pub-id pub-id-type="pmid">26341924</pub-id>
</element-citation></ref><ref id="B27-vaccines-13-00150"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hamed</surname><given-names>S.</given-names></name>
<name><surname>Shawky</surname><given-names>R.M.</given-names></name>
<name><surname>Emara</surname><given-names>M.</given-names></name>
<name><surname>Slauch</surname><given-names>J.M.</given-names></name>
<name><surname>Rao</surname><given-names>C.V.</given-names></name>
</person-group><article-title>HilE Is Required for Synergistic Activation of SPI-1 Gene Expression in <italic toggle="yes">Salmonella enterica</italic> Serovar Typhimurium</article-title><source>BMC Microbiol.</source><year>2021</year><volume>21</volume><elocation-id>49</elocation-id><pub-id pub-id-type="doi">10.1186/s12866-021-02110-8</pub-id><pub-id pub-id-type="pmid">33593291</pub-id>
</element-citation></ref><ref id="B28-vaccines-13-00150"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dawan</surname><given-names>J.</given-names></name>
<name><surname>Ahn</surname><given-names>J.</given-names></name>
</person-group><article-title>Assessment of Cross-Resistance Potential to Serial Antibiotic Treatments in Antibiotic-Resistant <italic toggle="yes">Salmonella</italic> Typhimurium</article-title><source>Microb. Pathog.</source><year>2020</year><volume>148</volume><fpage>104478</fpage><pub-id pub-id-type="doi">10.1016/j.micpath.2020.104478</pub-id><pub-id pub-id-type="pmid">32916245</pub-id>
</element-citation></ref><ref id="B29-vaccines-13-00150"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pei</surname><given-names>Y.</given-names></name>
<name><surname>Parreira</surname><given-names>V.R.</given-names></name>
<name><surname>Roland</surname><given-names>K.L.</given-names></name>
<name><surname>Curtiss</surname><given-names>R.</given-names></name>
<name><surname>Prescott</surname><given-names>J.F.</given-names></name>
</person-group><article-title>Assessment of Attenuated <italic toggle="yes">Salmonella</italic> Vaccine Strains in Controlling Experimental <italic toggle="yes">Salmonella</italic> Typhimurium Infection in Chickens</article-title><source>Can. J. Vet. Res.</source><year>2014</year><volume>78</volume><fpage>23</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">24396177</pub-id>
</element-citation></ref><ref id="B30-vaccines-13-00150"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gebauer</surname><given-names>J.</given-names></name>
<name><surname>Tesa&#x00159;&#x000ed;k</surname><given-names>R.</given-names></name>
<name><surname>Kr&#x000e1;lov&#x000e1;</surname><given-names>N.</given-names></name>
<name><surname>Havl&#x000ed;&#x0010d;kov&#x000e1;</surname><given-names>H.</given-names></name>
<name><surname>Matia&#x00161;ovic</surname><given-names>J.</given-names></name>
</person-group><article-title><italic toggle="yes">Salmonella</italic> Typhimurium-Based Inactivated Vaccine Containing a Wide Spectrum of Bacterial Antigens Which Mimics Protein Expression Changes during Different Stages of an Infection Process</article-title><source>Vet. Microbiol.</source><year>2023</year><volume>282</volume><elocation-id>109756</elocation-id><pub-id pub-id-type="doi">10.1016/j.vetmic.2023.109756</pub-id><pub-id pub-id-type="pmid">37141806</pub-id>
</element-citation></ref><ref id="B31-vaccines-13-00150"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Arricau</surname><given-names>N.</given-names></name>
<name><surname>Hermant</surname><given-names>D.</given-names></name>
<name><surname>Waxin</surname><given-names>H.</given-names></name>
<name><surname>Popoff</surname><given-names>M.Y.</given-names></name>
</person-group><article-title>Molecular Characterization of the <italic toggle="yes">Salmonella</italic> Typhi StpA Protein That Is Related to Both Yersinia YopE Cytotoxin and YopH Tyrosine Phosphatase</article-title><source>Res. Microbiol.</source><year>1997</year><volume>148</volume><fpage>21</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1016/S0923-2508(97)81896-7</pub-id><pub-id pub-id-type="pmid">9404501</pub-id>
</element-citation></ref><ref id="B32-vaccines-13-00150"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chandra</surname><given-names>S.</given-names></name>
<name><surname>Faisal</surname><given-names>S.M.</given-names></name>
<name><surname>Chen</surname><given-names>J.-W.</given-names></name>
<name><surname>Chen</surname><given-names>T.-T.</given-names></name>
<name><surname>McDonough</surname><given-names>S.P.</given-names></name>
<name><surname>Liu</surname><given-names>S.</given-names></name>
<name><surname>Moreira</surname><given-names>M.A.S.</given-names></name>
<name><surname>Akey</surname><given-names>B.L.</given-names></name>
<name><surname>Chang</surname><given-names>C.-F.</given-names></name>
<name><surname>Chang</surname><given-names>Y.-F.</given-names></name>
</person-group><article-title>Immune Response and Protective Efficacy of Live Attenuated <italic toggle="yes">Salmonella</italic> Vaccine Expressing Antigens of <italic toggle="yes">Mycobacterium Avium</italic> Subsp. <italic toggle="yes">Paratuberculosis</italic> against Challenge in Mice</article-title><source>Vaccine</source><year>2012</year><volume>31</volume><fpage>242</fpage><lpage>251</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2012.09.024</pub-id><pub-id pub-id-type="pmid">23000222</pub-id>
</element-citation></ref><ref id="B33-vaccines-13-00150"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Collins</surname><given-names>F.M.</given-names></name>
<name><surname>Carter</surname><given-names>P.B.</given-names></name>
</person-group><article-title>Comparative Immunogenicity of Heat-Killed and Living Oral <italic toggle="yes">Salmonella</italic> Vaccines</article-title><source>Infect. Immun.</source><year>1972</year><volume>6</volume><fpage>451</fpage><lpage>458</lpage><pub-id pub-id-type="doi">10.1128/iai.6.4.451-458.1972</pub-id><pub-id pub-id-type="pmid">4564282</pub-id>
</element-citation></ref><ref id="B34-vaccines-13-00150"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>&#x000d6;zdemir</surname><given-names>C.</given-names></name>
<name><surname>Ak&#x000e7;elik</surname><given-names>N.</given-names></name>
<name><surname>Neslihan &#x000d6;zdemir</surname><given-names>F.</given-names></name>
<name><surname>Evcili</surname><given-names>&#x00130;.</given-names></name>
<name><surname>Kahraman</surname><given-names>T.</given-names></name>
<name><surname>G&#x000fc;rsel</surname><given-names>&#x00130;.</given-names></name>
<name><surname>Ak&#x000e7;elik</surname><given-names>M.</given-names></name>
</person-group><article-title>The Role of bcsE Gene in the Pathogenicity of <italic toggle="yes">Salmonella</italic></article-title><source>Pathog. Dis.</source><year>2021</year><volume>79</volume><fpage>ftab037</fpage><pub-id pub-id-type="doi">10.1093/femspd/ftab037</pub-id><pub-id pub-id-type="pmid">34279609</pub-id>
</element-citation></ref><ref id="B35-vaccines-13-00150"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sirard</surname><given-names>J.</given-names></name>
<name><surname>Niedergang</surname><given-names>F.</given-names></name>
<name><surname>Kraehenbuhl</surname><given-names>J.</given-names></name>
</person-group><article-title>Live Attenuated <italic toggle="yes">Salmonella</italic>: A Paradigm of Mucosal Vaccines</article-title><source>Immunol. Rev.</source><year>1999</year><volume>171</volume><fpage>5</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1111/j.1600-065X.1999.tb01340.x</pub-id><pub-id pub-id-type="pmid">10582163</pub-id>
</element-citation></ref><ref id="B36-vaccines-13-00150"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lofton</surname><given-names>H.</given-names></name>
<name><surname>Anwar</surname><given-names>N.</given-names></name>
<name><surname>Rhen</surname><given-names>M.</given-names></name>
<name><surname>Andersson</surname><given-names>D.I.</given-names></name>
</person-group><article-title>Fitness of <italic toggle="yes">Salmonella</italic> Mutants Resistant to Antimicrobial Peptides</article-title><source>J. Antimicrob. Chemother.</source><year>2015</year><volume>70</volume><fpage>432</fpage><lpage>440</lpage><pub-id pub-id-type="doi">10.1093/jac/dku423</pub-id><pub-id pub-id-type="pmid">25362575</pub-id>
</element-citation></ref><ref id="B37-vaccines-13-00150"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pasetti</surname><given-names>M.F.</given-names></name>
<name><surname>Levine</surname><given-names>M.M.</given-names></name>
<name><surname>Sztein</surname><given-names>M.B.</given-names></name>
</person-group><article-title>Animal Models Paving the Way for Clinical Trials of Attenuated <italic toggle="yes">Salmonella Enterica</italic> Serovar Typhi Live Oral Vaccines and Live Vectors</article-title><source>Vaccine</source><year>2003</year><volume>21</volume><fpage>401</fpage><lpage>418</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(02)00472-3</pub-id><pub-id pub-id-type="pmid">12531639</pub-id>
</element-citation></ref><ref id="B38-vaccines-13-00150"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ji</surname><given-names>H.J.</given-names></name>
<name><surname>Jang</surname><given-names>A.-Y.</given-names></name>
<name><surname>Song</surname><given-names>J.Y.</given-names></name>
<name><surname>Ahn</surname><given-names>K.B.</given-names></name>
<name><surname>Han</surname><given-names>S.H.</given-names></name>
<name><surname>Bang</surname><given-names>S.J.</given-names></name>
<name><surname>Jung</surname><given-names>H.K.</given-names></name>
<name><surname>Hur</surname><given-names>J.</given-names></name>
<name><surname>Seo</surname><given-names>H.S.</given-names></name>
</person-group><article-title>Development of Live Attenuated <italic toggle="yes">Salmonella</italic> Typhimurium Vaccine Strain Using Radiation Mutation Enhancement Technology (R-MET)</article-title><source>Front. Immunol.</source><year>2022</year><volume>13</volume><elocation-id>931052</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2022.931052</pub-id><pub-id pub-id-type="pmid">35898510</pub-id>
</element-citation></ref><ref id="B39-vaccines-13-00150"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Desin</surname><given-names>T.S.</given-names></name>
<name><surname>K&#x000f6;ster</surname><given-names>W.</given-names></name>
<name><surname>Potter</surname><given-names>A.A.</given-names></name>
</person-group><article-title><italic toggle="yes">Salmonella</italic> Vaccines in Poultry: Past, Present and Future</article-title><source>Expert Rev. Vaccines</source><year>2013</year><volume>12</volume><fpage>87</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1586/erv.12.138</pub-id><pub-id pub-id-type="pmid">23256741</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="vaccines-13-00150-f001"><label>Figure 1</label><caption><p>Construction and biological characteristics of mutant ATCC14028&#x00394;<italic toggle="yes">sptP</italic>. (<bold>A</bold>) PCR validation of lateral primers. M, DL5000 DNA Marker; Lane 1: negative control; Lane 2: wild-type strain ATCC14028 genomic DNA; Lane 3: ATCC14028&#x00394;<italic toggle="yes">sptP</italic> genomic DNA. The PCR product for wild-type ATCC14028 measured 285 bp, while the ATCC14028&#x00394;<italic toggle="yes">sptP</italic> mutant, incorporating a chloramphenicol resistance gene, extended to 1145 bp. (<bold>B</bold>) Growth curves of ATCC14028 and its mutant ATCC14028&#x00394;<italic toggle="yes">sptP</italic>, cultured in LB medium at 37 &#x000b0;C and 180 rpm for 36 h, with optical density at 600 nm (OD<sub>600</sub>) measured bi-hourly.</p></caption><graphic xlink:href="vaccines-13-00150-g001" position="float"/></fig><fig position="float" id="vaccines-13-00150-f002"><label>Figure 2</label><caption><p>Invasion of ATCC14028 and ATCC14028&#x00394;<italic toggle="yes">sptP</italic> in RAW264.7 mouse macrophages. Bacterial counts were measured, and the results were expressed as Log CFU/mL. Data are presented as the mean &#x000b1; SEM. *** <italic toggle="yes">p</italic> &#x0003c;0.001.</p></caption><graphic xlink:href="vaccines-13-00150-g002" position="float"/></fig><fig position="float" id="vaccines-13-00150-f003"><label>Figure 3</label><caption><p>Histological analysis of mice after intraperitoneal injection of ATCC14028 and ATCC14028&#x00394;<italic toggle="yes">sptP</italic>. At 14 days, histopathological changes in the liver (<bold>A</bold>) and spleen (<bold>B</bold>) were detected by H&#x00026;E staining. The results were observed using an optical microscope at magnifications of 100&#x000d7; and 400&#x000d7;. Note: The black and red arrows indicate inflammatory cells.</p></caption><graphic xlink:href="vaccines-13-00150-g003" position="float"/></fig><fig position="float" id="vaccines-13-00150-f004"><label>Figure 4</label><caption><p>The invasion capacity of ATCC14028 and ATCC14028&#x00394;<italic toggle="yes">sptP</italic> in mouse organs. Bacterial invasion and persistence in the liver (<bold>A</bold>), spleen (<bold>B</bold>), lungs (<bold>C</bold>), and kidneys (<bold>D</bold>) of mice after intraperitoneal injection of ATCC14028 and ATCC14028&#x00394;<italic toggle="yes">sptP</italic> at 2 &#x000d7; 10<sup>4</sup> CFUs. Bacterial counts were measured, and the results were expressed as Log CFU/mL. Data are presented as the mean &#x000b1; SEM, where * denotes significance levels: * <italic toggle="yes">p</italic> &#x0003c; 0.05, and *** <italic toggle="yes">p</italic> &#x0003c; 0.001.</p></caption><graphic xlink:href="vaccines-13-00150-g004" position="float"/></fig><fig position="float" id="vaccines-13-00150-f005"><label>Figure 5</label><caption><p>Immunoprotective effect and antibody levels of ATCC14028&#x00394;<italic toggle="yes">sptP</italic>. Histopathological changes in the liver (<bold>A</bold>) and spleen (<bold>B</bold>) after immunization with ATCC14028&#x00394;<italic toggle="yes">sptP</italic> were detected via H&#x00026;E staining. (<bold>C</bold>) Survival rates of mice immunized with ATCC14028&#x00394;<italic toggle="yes">sptP</italic> post-challenge. (<bold>D</bold>) Testing of serum IgG expression levels in mice. Data are presented as the mean &#x000b1; SEM. * <italic toggle="yes">p</italic> &#x02264; 0.05, ** <italic toggle="yes">p</italic> &#x02264; 0.01, *** <italic toggle="yes">p</italic> &#x0003c;0.001, and ns indicates no significant difference (<italic toggle="yes">p</italic> &#x02265; 0.05).</p></caption><graphic xlink:href="vaccines-13-00150-g005" position="float"/></fig><table-wrap position="float" id="vaccines-13-00150-t001"><object-id pub-id-type="pii">vaccines-13-00150-t001_Table 1</object-id><label>Table 1</label><caption><p>Primers used in this study.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Primers</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Sequences (5&#x02032;-3&#x02032;) <sup>1</sup></th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Production Size</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Usage</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Source</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">sptP</italic>-cat-F</td><td align="center" valign="middle" rowspan="1" colspan="1">GTTTGCTGATTAATTGGAATGCTGCTGACCGCAAATCGTGCAGGCCCAGttacgccccgccctgccac</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">960 bp</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1"><italic toggle="yes">sptP</italic> gene homologous arms</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">This study</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">sptP</italic>-cat-R</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AGAAAATAGAACCGGCGCGCCAATGCCACAGACGATGAGCGGACCGCAtacctgtgacggaagatcacttc</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">sptP</italic>-out-F</td><td align="center" valign="middle" rowspan="1" colspan="1">GTACGAACCGCTAATGCCACAGG</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1145 bp or <break/>285 bp</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Identification of <italic toggle="yes">sptP</italic> mutant</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">This study</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">sptP</italic>-out-R</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GAGAGGTGGTTGTAAAGCTCTACTCATG</td></tr></tbody></table><table-wrap-foot><fn><p><sup>1</sup> Lowercase letter: Cmr cassette amplification.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="vaccines-13-00150-t002"><object-id pub-id-type="pii">vaccines-13-00150-t002_Table 2</object-id><label>Table 2</label><caption><p>Median lethal dose of ATCC14028 and ATCC14028&#x00394;<italic toggle="yes">sptP</italic> injected intraperitoneally in mice.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Groups</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Challenge Dose (CFUs)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Number of Dead Mice/Total Number of Mice</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mortality</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">LD<sub>50</sub> (CFUs)</th></tr></thead><tbody><tr><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">ATCC14028</td><td align="center" valign="middle" rowspan="1" colspan="1">10<sup>5</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">0/5</td><td align="center" valign="middle" rowspan="1" colspan="1">0%</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">5.01 &#x000d7; 10<sup>5</sup></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">10<sup>6</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">4/5</td><td align="center" valign="middle" rowspan="1" colspan="1">80%</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">10<sup>7</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">5/5</td><td align="center" valign="middle" rowspan="1" colspan="1">100%</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">10<sup>8</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">5/5</td><td align="center" valign="middle" rowspan="1" colspan="1">100%</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">10<sup>9</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">5/5</td><td align="center" valign="middle" rowspan="1" colspan="1">100%</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>10</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5/5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100%</td></tr><tr><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">ATCC14028&#x00394;<italic toggle="yes">sptP</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">10<sup>5</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">0/5</td><td align="center" valign="middle" rowspan="1" colspan="1">0%</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">2 &#x000d7; 10<sup>7</sup></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">10<sup>6</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">0/5</td><td align="center" valign="middle" rowspan="1" colspan="1">0%</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">10<sup>7</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">2/5</td><td align="center" valign="middle" rowspan="1" colspan="1">40%</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">10<sup>8</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">4/5</td><td align="center" valign="middle" rowspan="1" colspan="1">80%</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">10<sup>9</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">5/5</td><td align="center" valign="middle" rowspan="1" colspan="1">100%</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>10</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5/5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100%</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PBS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr></tbody></table></table-wrap></floats-group></article>